{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:27:29Z","timestamp":1789057649762,"version":"build-2803163510"},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1989,11]]},"abstract":"<jats:p> Despite the clinical experience with Ommaya reservoir-facilitated intraventricular methotrexate (MTX) therapy, established age-related dosage guidelines do not exist. In an attempt to design such a schedule, 49 courses of intra-Ommaya MTX (median dose, 6 mg) administered to 12 patients were studied. Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol\/L. Median CSF [MTX] at 24 hours was 4.6 mumol\/L, and at 48 hours was 1.05 mumol\/L. Median MTX half-life (t1\/2) was 5.7 hours. A CSF [MTX] greater than 1 mumol\/L was maintained for 24 hours in all but one course and for 48 hours in half of the courses. No correlations were found between MTX dose, patient age, [MTX], t1\/2 or prior therapy. Considerable intra- and interpatient variability was seen in MTX disposition, emphasizing the need to monitor [MTX] with each course. A schedule for intraventricular MTX with an initial dose of 6 mg and supplemental doses of 6, 4, or 2 mg at 24 and 48 hours according to serial measurements of intraventricular [MTX] should be initiated to provide a minimum CSF [MTX] of 1 mumol\/L for 72 hours. <\/jats:p>","DOI":"10.1200\/jco.1989.7.11.1741","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:57:38Z","timestamp":1487872658000},"page":"1741-1747","source":"Crossref","is-referenced-by-count":18,"title":["Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing."],"prefix":"10.1200","volume":"7","author":[{"given":"D R","family":"Strother","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Glynn-Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kovnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S B","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1989.7.11.1741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:31:38Z","timestamp":1653521498000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1989.7.11.1741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,11]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1989,11]]}},"alternative-id":["10.1200\/JCO.1989.7.11.1741"],"URL":"https:\/\/doi.org\/10.1200\/jco.1989.7.11.1741","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,11]]}}}